{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T22:30:27Z","timestamp":1785796227149,"version":"3.56.0"},"reference-count":331,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,4]],"date-time":"2021-11-04T00:00:00Z","timestamp":1635984000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Peptides"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.peptides.2021.170683","type":"journal-article","created":{"date-parts":[[2021,11,5]],"date-time":"2021-11-05T17:51:51Z","timestamp":1636134711000},"page":"170683","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"special_numbering":"C","title":["Peptides in the regulation of glucagon secretion"],"prefix":"10.1016","volume":"148","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7944-9342","authenticated-orcid":false,"given":"Daniel B.","family":"Andersen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6853-3805","authenticated-orcid":false,"given":"Jens J.","family":"Holst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.peptides.2021.170683_bib0005","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/S0140-6736(75)92375-2","article-title":"The Essential Role of Glucagon in the Pathogenesis of Diabetes Mellitus","volume":"305","author":"Unger","year":"1975","journal-title":"Lancet."},{"key":"10.1016\/j.peptides.2021.170683_bib0010","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1056\/NEJM197808312990901","article-title":"Hyperglucagonemia and its suppression","volume":"299","author":"Raskin","year":"1978","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.peptides.2021.170683_bib0015","doi-asserted-by":"crossref","first-page":"391","DOI":"10.2337\/db10-0426","article-title":"Glucagon receptor knockout prevents insulin-deficient type 1 diabetes in mice","volume":"60","author":"Lee","year":"2011","journal-title":"Diabetes"},{"key":"10.1016\/j.peptides.2021.170683_bib0020","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.peptides.2017.11.013","article-title":"Problem or solution: the strange story of glucagon","volume":"100","author":"Scott","year":"2018","journal-title":"Peptides"},{"key":"10.1016\/j.peptides.2021.170683_bib0025","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s001250051322","article-title":"Autonomic regulation of islet hormone secretion - Implications for health and disease","volume":"43","author":"Ahr\u00e9n","year":"2000","journal-title":"Diabetologia"},{"key":"10.1016\/j.peptides.2021.170683_bib0030","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1210\/er.2006-0007","article-title":"A-cells of the endocrine pancreas: 35 years of research but the enigma remains","volume":"28","author":"Gromada","year":"2007","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.peptides.2021.170683_bib0035","doi-asserted-by":"crossref","first-page":"542","DOI":"10.2337\/dbi19-0021","article-title":"A primary role for \u03b1-cells as amino acid sensors","volume":"69","author":"Danielle Dean","year":"2020","journal-title":"Diabetes"},{"key":"10.1016\/j.peptides.2021.170683_bib0040","first-page":"3300","article-title":"CPT1a-dependent long-chain fatty acid oxidation contributes to maintaining glucagon secretion from pancreatic islets","volume":"23","author":"Briant","year":"2018","journal-title":"CellReports."},{"key":"10.1016\/j.peptides.2021.170683_bib0045","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1463-1326.2011.01450.x","article-title":"Regulation of glucagon secretion by glucose: paracrine, intrinsic or both?","volume":"13","author":"Walker","year":"2011","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.peptides.2021.170683_bib0050","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.mayocp.2017.12.003","article-title":"The role of glucagon in the pathophysiology and treatment of type 2 diabetes","volume":"93","author":"H\u00e6dersdal","year":"2018","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.peptides.2021.170683_bib0055","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/BF00408354","article-title":"Abnormal glucagon response to arginine and its normalization in obese hyperinsulinaemic patients with glucose intolerance: importance of insulin action on pancreatic Alpha cells","volume":"34","author":"Hamaguchi","year":"1991","journal-title":"Diabetologia."},{"key":"10.1016\/j.peptides.2021.170683_bib0060","doi-asserted-by":"crossref","first-page":"33487","DOI":"10.1074\/jbc.M506276200","article-title":"Glucose-regulated glucagon secretion requires insulin receptor expression in pancreatic \u03b1-cells","volume":"280","author":"Diao","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.peptides.2021.170683_bib0065","doi-asserted-by":"crossref","DOI":"10.2337\/diabetes.54.6.1808","article-title":"\u03b2-cell secretory products activate \u03b1-cell ATP-dependent potassium channels to inhibit glucagon release","author":"Franklin","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.peptides.2021.170683_bib0070","doi-asserted-by":"crossref","DOI":"10.1111\/apha.13464","article-title":"In the rat pancreas, somatostatin tonically inhibits glucagon secretion and is required for glucose-induced inhibition of glucagon secretion","volume":"229","author":"Xu","year":"2020","journal-title":"Acta Physiol."},{"key":"10.1016\/j.peptides.2021.170683_bib0075","doi-asserted-by":"crossref","DOI":"10.2337\/diabetes.54.6.1789","article-title":"Glucose or insulin, but not zinc ions, inhibit glucagon secretion from mouse pancreatic \u03b1-cells","author":"Ravier","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.peptides.2021.170683_bib0080","doi-asserted-by":"crossref","DOI":"10.1172\/JCI107638","article-title":"The effect of insulin on the alpha cell response to hyperglycemia in long standing alloxan diabetes","author":"Braaten","year":"1974","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.peptides.2021.170683_bib0085","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2337\/diab.25.4.275","article-title":"Glucagon secretion from the perfused pancreas of streptozotocin treated rats","volume":"25","author":"Weir","year":"1976","journal-title":"Diabetes"},{"key":"10.1016\/j.peptides.2021.170683_bib0090","article-title":"Evidence for metabolic regulation of pancreatic glucagon secretion by L-glutamine","author":"Ostenson","year":"1985","journal-title":"European Society of Endocrinology"},{"key":"10.1016\/j.peptides.2021.170683_bib0095","doi-asserted-by":"crossref","DOI":"10.1172\/JCI111658","article-title":"Insulin within islets is a physiologic glucagon release inhibitor","author":"Maruyama","year":"1984","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.peptides.2021.170683_bib0100","doi-asserted-by":"crossref","first-page":"E660","DOI":"10.1152\/ajpendo.00410.2018","article-title":"Glucose and amino acid metabolism in mice depend mutually on glucagon and insulin receptor signaling","volume":"316","author":"Galsgaard","year":"2019","journal-title":"Am. J. Physiol. - Endocrinol. Metab."},{"key":"10.1016\/j.peptides.2021.170683_bib0105","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.cmet.2009.02.007","article-title":"Insulin signaling in \u03b1 cells modulates glucagon secretion in vivo","volume":"9","author":"Kawamori","year":"2009","journal-title":"Cell Metab."},{"key":"10.1016\/j.peptides.2021.170683_bib0110","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1152\/ajpcell.00115.2012","article-title":"Regulation of the human Na+-dependent glucose cotransporter hSGLT2","volume":"303","author":"Ghezzi","year":"2012","journal-title":"Am. J. Physiol. - Cell Physiol."},{"key":"10.1016\/j.peptides.2021.170683_bib0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-018-08193-8","article-title":"Insulin inhibits glucagon release by SGLT2-induced stimulation of somatostatin secretion","volume":"10","author":"Vergari","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.peptides.2021.170683_bib0120","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1007\/s00125-020-05288-0","article-title":"Paracrine regulation of somatostatin secretion by insulin and glucagon in mouse pancreatic islets","volume":"64","author":"Svendsen","year":"2021","journal-title":"Diabetologia."},{"key":"10.1016\/j.peptides.2021.170683_bib0125","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3109\/03009734.2016.1164769","article-title":"Pancreatic islet blood flow and its measurement","volume":"121","author":"Jansson","year":"2016","journal-title":"Ups. J. Med. Sci."},{"key":"10.1016\/j.peptides.2021.170683_bib0130","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s40262-013-0104-3","article-title":"Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose Co-transporter type 2","volume":"53","author":"Kasichayanula","year":"2014","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.peptides.2021.170683_bib0135","doi-asserted-by":"crossref","DOI":"10.1007\/s00125-019-4849-6","article-title":"No direct effect of SGLT2 activity on glucagon secretion","author":"Kuhre","year":"2019","journal-title":"Diabetologia."},{"key":"10.1016\/j.peptides.2021.170683_bib0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.molmet.2018.10.009","article-title":"SGLT1 in pancreatic \u03b1 cells regulates glucagon secretion in mice, possibly explaining the distinct effects of SGLT2 inhibitors on plasma glucagon levels","volume":"19","author":"Suga","year":"2019","journal-title":"Mol. Metab."},{"key":"10.1016\/j.peptides.2021.170683_bib0145","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.2337\/db17-1278","article-title":"Endogenous glucose production and hormonal changes in response to canagliflozin and liraglutide combination therapy","volume":"67","author":"Martinez","year":"2018","journal-title":"Diabetes."},{"key":"10.1016\/j.peptides.2021.170683_bib0150","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1172\/JCI72227","article-title":"Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients","volume":"124","author":"Ferrannini","year":"2014","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.peptides.2021.170683_bib0155","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1172\/JCI70704","article-title":"Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production","volume":"124","author":"Merovci","year":"2014","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.peptides.2021.170683_bib0160","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.2337\/db20-0369","article-title":"The role of glucagon in the acute therapeutic effects of SGLT2 inhibition","volume":"69","author":"H\u00e6dersdal","year":"2020","journal-title":"Diabetes"},{"key":"10.1016\/j.peptides.2021.170683_bib0165","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1007\/s00125-014-3486-3","article-title":"The influence of glucagon on postprandial hyperglycaemia in children 5 years after onset of type 1 diabetes","volume":"58","author":"Fredheim","year":"2015","journal-title":"Diabetologia."},{"key":"10.1016\/j.peptides.2021.170683_bib0170","doi-asserted-by":"crossref","DOI":"10.1172\/JCI115375","article-title":"Intra-islet insulin permits glucose to directly suppress pancreatic A cell function","author":"Greenbaum","year":"1991","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.peptides.2021.170683_bib0175","first-page":"118","article-title":"Continuous intraperitoneal insulin infusion partly restores the glucagon response to hypoglycaemia in type 1 diabetic patients","volume":"26","author":"Oskarsson","year":"2000","journal-title":"Diabetes Metab."},{"key":"10.1016\/j.peptides.2021.170683_bib0180","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s00125-017-4535-5","article-title":"Evidence of a liver\u2013alpha cell axis in humans: hepatic insulin resistance attenuates relationship between fasting plasma glucagon and glucagonotropic amino acids","volume":"61","author":"Wewer Albrechtsen","year":"2018","journal-title":"Diabetologia."},{"key":"10.1016\/j.peptides.2021.170683_bib0185","doi-asserted-by":"crossref","first-page":"4049","DOI":"10.3390\/jcm9124049","article-title":"The vicious circle of hepatic glucagon resistance in non-alcoholic fatty liver disease","volume":"9","author":"Galsgaard","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.peptides.2021.170683_bib0190","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1210\/er.2018-00251","article-title":"The Liver-\u03b1-Cell Axis and type 2 diabetes","volume":"40","author":"Wewer Albrechtsen","year":"2019","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.peptides.2021.170683_bib0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101080","article-title":"Glucagon acutely regulates hepatic amino acid catabolism and the effect may be disturbed by steatosis","volume":"42","author":"Winther-S\u00f8rensen","year":"2020","journal-title":"Mol. Metab."},{"key":"10.1016\/j.peptides.2021.170683_bib0200","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/nrm.2017.89","article-title":"Biochemical and cellular properties of insulin receptor signalling","volume":"19","author":"Haeusler","year":"2018","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.peptides.2021.170683_bib0205","doi-asserted-by":"crossref","first-page":"7369","DOI":"10.1074\/jbc.M408560200","article-title":"Protein kinase B activity is sufficient to mimic the effect of insulin on glucagon gene transcription","volume":"280","author":"Schinner","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.peptides.2021.170683_bib0210","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0168-8227(99)00021-2","article-title":"Insulin inhibits glucagon secretion by the activation of PI3-kinase in In-R1-G9 cells","volume":"44","author":"Kaneko","year":"1999","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.peptides.2021.170683_bib0215","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1007\/s00125-006-0511-1","article-title":"Glucose inhibits glucagon secretion by a direct effect on mouse pancreatic alpha cells","volume":"50","author":"Vieira","year":"2007","journal-title":"Diabetologia."},{"key":"10.1016\/j.peptides.2021.170683_bib0220","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1172\/JCI107823","article-title":"Characterization of the effects of arginine and glucose on glucagon and insulin release from the perfused rat pancreas","volume":"54","author":"Gerich","year":"1974","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.peptides.2021.170683_bib0225","first-page":"1","article-title":"\u03b4-Cells: The Neighborhood Watch in the Islet Community","volume":"10","author":"Gao","year":"2021","journal-title":"Biology (Basel)."},{"key":"10.1016\/j.peptides.2021.170683_bib0230","article-title":"Antagonizing somatostatin receptor subtype 2 and 5 reduces blood glucose in a gut- and GLP-1R-dependent manner","volume":"6","author":"Jepsen","year":"2021","journal-title":"JCI Insight"},{"key":"10.1016\/j.peptides.2021.170683_bib0235","doi-asserted-by":"crossref","first-page":"876","DOI":"10.2337\/diab.23.11.876","article-title":"Inhibition of pancreatic glucagon responses to arginine by somatostatin in normal man and in insulin dependent diabetics","volume":"23","author":"Gerich","year":"1974","journal-title":"Diabetes."},{"key":"10.1016\/j.peptides.2021.170683_bib0240","doi-asserted-by":"crossref","first-page":"592","DOI":"10.2337\/diab.36.5.592","article-title":"Pancreatic somatostatin is a mediator of glucagon inhibition by hyperglycemia","volume":"36","author":"Klaff","year":"1987","journal-title":"Diabetes."},{"key":"10.1016\/j.peptides.2021.170683_bib0245","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1152\/ajpendo.90372.2008","article-title":"Amplification of pulsatile glucagon counterregulation by switch-off of \u03b1-cell-suppressing signals in streptozotocin-treated rats","volume":"295","author":"Farhy","year":"2008","journal-title":"Am. J. Physiol. - Endocrinol. Metab."},{"key":"10.1016\/j.peptides.2021.170683_bib0250","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1007\/s00125-017-4315-2","article-title":"The role of somatostatin in GLP-1-induced inhibition of glucagon secretion in mice","volume":"60","author":"\u00d8rgaard","year":"2017","journal-title":"Diabetologia."},{"key":"10.1016\/j.peptides.2021.170683_bib0255","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1007\/s00125-016-4033-1","article-title":"Transcriptomic profiling of pancreatic alpha, beta and delta cell populations identifies delta cells as a principal target for ghrelin in mouse islets","volume":"59","author":"Adriaenssens","year":"2016","journal-title":"Diabetologia."},{"key":"10.1016\/j.peptides.2021.170683_bib0260","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.2337\/db17-0880","article-title":"Somatostatin is only partly required for the glucagonostatic effect of glucose but is necessary for the glucagonostatic effect of K ATP channel blockers","volume":"67","author":"Lai","year":"2018","journal-title":"Diabetes."},{"key":"10.1016\/j.peptides.2021.170683_bib0265","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2337\/diabetes.48.1.77","article-title":"Subtype-selective expression of the five somatostatin receptors (hSSTR1-5) in human pancreatic islet cells: a quantitative double-label immunohistochemical analysis","volume":"48","author":"Kumar","year":"1999","journal-title":"Diabetes"},{"key":"10.1016\/j.peptides.2021.170683_bib0270","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1152\/physiol.00029.2018","article-title":"The difference \u03b4-cells make in glucose control","volume":"33","author":"Huising","year":"2018","journal-title":"Physiology"},{"key":"10.1016\/j.peptides.2021.170683_bib0275","doi-asserted-by":"crossref","first-page":"E1107","DOI":"10.1152\/ajpendo.00207.2012","article-title":"SSTR2 is the functionally dominant somatostatin receptor in human pancreatic \u03b2- and \u03b1-cells","volume":"303","author":"Kailey","year":"2012","journal-title":"Am. J. Physiol. - Endocrinol. Metab."},{"key":"10.1016\/j.peptides.2021.170683_bib0280","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1152\/ajpendo.00207.2012","article-title":"SSTR2 is the functionally dominant somatostatin receptor in human pancreatic \u03b2- and \u03b1-cells","volume":"303","author":"Kailey","year":"2012","journal-title":"Am. J. Physiol. - Endocrinol. Metab."},{"key":"10.1016\/j.peptides.2021.170683_bib0285","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/j.1469-7793.2001.00519.x","article-title":"Somatostatin inhibits exocytosis in rat pancreatic \u03b1-cells by Gi2-dependent activation of calcineurin and depriming of secretory granules","volume":"535","author":"Gromada","year":"2001","journal-title":"J. Physiol."},{"key":"10.1016\/j.peptides.2021.170683_bib0290","doi-asserted-by":"crossref","first-page":"E130","DOI":"10.1152\/ajpendo.00344.2014","article-title":"Somatostatin and insulin mediate glucose-inhibited glucagon secretion in the pancreatic \u03b1-cell by lowering cAMP","volume":"308","author":"Elliott","year":"2015","journal-title":"Am. J. Physiol. - Endocrinol. Metab."},{"key":"10.1016\/j.peptides.2021.170683_bib0295","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1007\/s00125-019-4857-6","article-title":"Glucose controls glucagon secretion by directly modulating cAMP in alpha cells","volume":"62","author":"Yu","year":"2019","journal-title":"Diabetologia."},{"key":"10.1016\/j.peptides.2021.170683_bib0300","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/dom.12993","article-title":"cAMP signalling in insulin and glucagon secretion, Diabetes","volume":"19","author":"Tengholm","year":"2017","journal-title":"Obes. Metab."},{"key":"10.1016\/j.peptides.2021.170683_bib0305","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.2337\/db12-0347","article-title":"Tolbutamide controls glucagon release from mouse islets differently than glucose: Involvement of KATP channels from both \u03b1-cells and \u03b4-cells","volume":"62","author":"Cheng-Xue","year":"2013","journal-title":"Diabetes."},{"key":"10.1016\/j.peptides.2021.170683_bib0310","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1007\/s00125-014-3279-8","article-title":"ATP-regulated potassium channels and voltage-gated calcium channels in pancreatic alpha and beta cells: similar functions but reciprocal effects on secretion","volume":"57","author":"Rorsman","year":"2014","journal-title":"Diabetologia."},{"key":"10.1016\/j.peptides.2021.170683_bib0315","doi-asserted-by":"crossref","first-page":"4861","DOI":"10.1210\/en.2005-0800","article-title":"Glucose stimulates glucagon release in single rat \u03b1-cells by mechanisms that mirror the stimulus-secretion coupling in \u03b2-cells","volume":"146","author":"Olsen","year":"2005","journal-title":"Endocrinology."},{"key":"10.1016\/j.peptides.2021.170683_bib0320","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1113\/JP274581","article-title":"\u0394-Cells and B-Cells Are Electrically Coupled and Regulate A-Cell Activity Via Somatostatin","volume":"596","author":"Briant","year":"2018","journal-title":"J. Physiol."},{"key":"10.1016\/j.peptides.2021.170683_bib0325","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.cmet.2013.10.014","article-title":"Role of KATP channels in glucose-regulated glucagon secretion and impaired counterregulation in type 2 diabetes","volume":"18","author":"Zhang","year":"2013","journal-title":"Cell Metab."},{"key":"10.1016\/j.peptides.2021.170683_bib0330","doi-asserted-by":"crossref","first-page":"101268","DOI":"10.1016\/j.molmet.2021.101268","article-title":"KATP channel blockers control glucagon secretion by distinct mechanisms: a direct stimulation of \u03b1-cells involving a [Ca2+]c rise and an indirect inhibition mediated by somatostatin","volume":"53","author":"Singh","year":"2021","journal-title":"Mol. Metab."},{"key":"10.1016\/j.peptides.2021.170683_bib0335","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/dom.12012","article-title":"Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study","volume":"15","author":"Nauck","year":"2013","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.peptides.2021.170683_bib0340","doi-asserted-by":"crossref","first-page":"4165","DOI":"10.1210\/jc.2006-1932","article-title":"The dipeptidyl peptidase 4 inhibitor vildagliptin does not accentuate glibenclamide-induced hypoglycemia but reduces glucose-induced glucagon-like peptide 1 and gastric inhibitory polypeptide secretion","volume":"92","author":"El-Ouaghlidi","year":"2007","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.peptides.2021.170683_bib0345","first-page":"1094","article-title":"Glucose stimulates somatostatin secretion in pancreatic \u03b4-cells by cAMP-dependent intracellular Ca2+ release","volume":"151","author":"Denwood","year":"2018","journal-title":"J. Gen. Physiol."},{"key":"10.1016\/j.peptides.2021.170683_bib0350","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/0026-0495(80)90194-8","article-title":"Selective effect of some somatostatin analogs on glucagon as opposed to insulin release in rats in vivo","volume":"29","author":"Lins","year":"1980","journal-title":"Metabolism."},{"key":"10.1016\/j.peptides.2021.170683_bib0355","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/BF00265096","article-title":"Sensitivity of rat pancreatic A and B cells to somatostatin","volume":"32","author":"Schuit","year":"1989","journal-title":"Diabetologia."},{"key":"10.1016\/j.peptides.2021.170683_bib0360","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/j.metabol.2005.04.022","article-title":"The short-term effect of fatty acids on glucagon secretion is influenced by their chain length, spatial configuration, and degree of unsaturation: studies in vitro","volume":"54","author":"Hong","year":"2005","journal-title":"Metabolism."},{"key":"10.1016\/j.peptides.2021.170683_bib0365","doi-asserted-by":"crossref","DOI":"10.1172\/JCI105916","article-title":"Characterization of response of circulating glucagon to intraduodenal and intravenous administration of amino acids","author":"Ohneda","year":"1968","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.peptides.2021.170683_bib0370","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.0237106100","article-title":"Lower blood glucose, hyperglucagonemia, and pancreatic \u03b1 cell hyperplasia in glucagon receptor knockout mice","author":"Gelling","year":"2003","journal-title":"PNAS"},{"key":"10.1016\/j.peptides.2021.170683_bib0375","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101021","article-title":"Reduced somatostatin signalling leads to hypersecretion of glucagon in mice fed a high-fat diet","volume":"40","author":"Kellard","year":"2020","journal-title":"Mol. Metab."},{"key":"10.1016\/j.peptides.2021.170683_bib0380","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1097\/MPA.0b013e3181cf1878","article-title":"Somatostatin receptor subtypes in human type 2 diabetic islets","volume":"39","author":"Portela-Gomes","year":"2010","journal-title":"Pancreas."},{"key":"10.1016\/j.peptides.2021.170683_bib0385","doi-asserted-by":"crossref","first-page":"197","DOI":"10.2337\/db11-0690","article-title":"Somatostatin receptor type 2 antagonism improves glucagon and corticosterone counterregulatory responses to hypoglycemia in streptozotocin-induced diabetic rats","volume":"61","author":"Yue","year":"2012","journal-title":"Diabetes."},{"key":"10.1016\/j.peptides.2021.170683_bib0390","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.2337\/db13-0164","article-title":"Somatostatin receptor type 2 antagonism improves glucagon counterregulation in biobreeding diabetic rats","volume":"62","author":"Karimian","year":"2013","journal-title":"Diabetes."},{"key":"10.1016\/j.peptides.2021.170683_bib0395","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.diabet.2017.05.003","article-title":"Effects of anti-somatostatin agents on glucose metabolism","volume":"43","author":"Verg\u00e8s","year":"2017","journal-title":"Diabetes Metab."},{"key":"10.1016\/j.peptides.2021.170683_bib0400","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.1210\/jc.2013-1771","article-title":"Hyperglycemia associated with pasireotide: Results from a mechanistic study in healthy volunteers","volume":"98","author":"Henry","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.peptides.2021.170683_bib0405","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S0006-2952(99)00010-6","article-title":"Inhibition of human pancreatic islet insulin release by receptor-selective somatostatin analogs directed to somatostatin receptor subtype 5","volume":"57","author":"Zambre","year":"1999","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.peptides.2021.170683_bib0410","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1210\/en.2006-1659","article-title":"Somatostatin receptor subtype-2-deficient mice with diet-induced obesity have hyperglycemia, nonfasting hyperglucagonemia, and decreased hepatic glycogen deposition","volume":"148","author":"Singh","year":"2007","journal-title":"Endocrinology."},{"key":"10.1016\/j.peptides.2021.170683_bib0415","doi-asserted-by":"crossref","first-page":"429","DOI":"10.2337\/diacare.8.5.429","article-title":"Reduced postprandial hyperglycemia after subcutaneous injection of a somatostatin-analogue (SMS 201-995) in insulin-dependent diabetes mellitus","volume":"8","author":"Spinas","year":"1985","journal-title":"Diabetes Care"},{"key":"10.1016\/j.peptides.2021.170683_bib0420","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s002280050174","article-title":"Effect of octreotide on blood glucose and counterregulatory hormones in insulin-dependent diabetic patients: the role of dose and route of administration","volume":"51","author":"Lunetta","year":"1996","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.peptides.2021.170683_bib0425","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0168-8227(97)00094-6","article-title":"Effects of octreotide on glycaemic control, glucose disposal, hepatic glucose production and counterregulatory hormones secretion in type 1 and type 2 insulin treated diabetic patients","volume":"38","author":"Lunetta","year":"1997","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.peptides.2021.170683_bib0430","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1055\/s-2007-1010784","article-title":"Postprandial glycaemic effects of a long-acting somatostatin analogue (octreotide) in non-insulin dependent diabetes mellitus","volume":"20","author":"Williams","year":"1988","journal-title":"Horm. Metab. Res."},{"key":"10.1016\/j.peptides.2021.170683_bib0435","doi-asserted-by":"crossref","DOI":"10.1007\/s12020-021-02782-2","article-title":"Long-term safety and efficacy of long-acting pasireotide in acromegaly","author":"Akirov","year":"2021","journal-title":"Endocrine."},{"key":"10.1016\/j.peptides.2021.170683_bib0440","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.1210\/jcem.87.7.8665","article-title":"Somatostatin analogs in acromegaly","volume":"87","author":"Freda","year":"2002","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.peptides.2021.170683_bib0445","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1530\/EJE-10-0811","article-title":"Effects of high-dose octreotide lar on glucose metabolism in patients with acromegaly inadequately controlled by conventional somatostatin analog therapy","volume":"164","author":"Mazziotti","year":"2011","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.peptides.2021.170683_bib0450","doi-asserted-by":"crossref","first-page":"3216","DOI":"10.1210\/en.2002-0087","article-title":"Urocortin III is expressed in pancreatic \u03b2-cells and stimulates insulin and glucagon secretion","volume":"144","author":"Li","year":"2003","journal-title":"Endocrinology."},{"key":"10.1016\/j.peptides.2021.170683_bib0455","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/nm.3872","article-title":"Urocortin3 mediates somatostatin-dependent negative feedback control of insulin secretion","volume":"21","author":"Van Der Meulen","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.peptides.2021.170683_bib0460","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0196-9781(01)00601-5","article-title":"Distribution of pancreatic polypeptide and peptide YY","volume":"23","author":"Ekblad","year":"2002","journal-title":"Peptides."},{"key":"10.1016\/j.peptides.2021.170683_bib0465","doi-asserted-by":"crossref","first-page":"523","DOI":"10.2337\/diab.35.5.523","article-title":"Modulatory effect of glucose, amino acids, and secretin on CCK-8-induced somatostatin and pancreatic polypeptide release in dogs","volume":"35","author":"Schusdziarra","year":"1986","journal-title":"Diabetes."},{"key":"10.1016\/j.peptides.2021.170683_bib0470","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1210\/jcem-54-1-48","article-title":"Pancreatic polypeptide responses to hypoglycemia in chronic autonomic failure","volume":"54","author":"Polinsky","year":"1982","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.peptides.2021.170683_bib0475","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.npep.2012.08.005","article-title":"Neuropeptide Y, peptide YY and pancreatic polypeptide in the gut-brain axis","volume":"46","author":"Holzer","year":"2012","journal-title":"Neuropeptides."},{"key":"10.1016\/j.peptides.2021.170683_bib0480","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S0166-2236(96)01057-0","article-title":"Y-receptor subtypes - How many more?","volume":"20","author":"Blomqvist","year":"1997","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.peptides.2021.170683_bib0485","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.1016\/j.febslet.2014.07.005","article-title":"Pancreatic polypeptide inhibits somatostatin secretion","volume":"588","author":"Kim","year":"2014","journal-title":"FEBS Lett."},{"key":"10.1016\/j.peptides.2021.170683_bib0490","doi-asserted-by":"crossref","first-page":"3989","DOI":"10.1210\/jc.2003-030630","article-title":"Pancreatic polypeptide reduces appetite and food intake in humans","volume":"88","author":"Batterham","year":"2003","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.peptides.2021.170683_bib0495","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/nrendo.2010.93","article-title":"Bowels control brain: gut hormones and obesity","volume":"6","author":"Field","year":"2010","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.peptides.2021.170683_bib0500","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.bbagen.2014.11.005","article-title":"Pancreatic polypeptide regulates glucagon release through PPYR1 receptors expressed in mouse and human alpha-cells","volume":"1850","author":"Arag\u00f3n","year":"2015","journal-title":"Biochim. Biophys. Acta - Gen. Subj."},{"key":"10.1016\/j.peptides.2021.170683_bib0505","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1210\/endocr\/bqab070","article-title":"Regulation of pancreatic \u03b2-cell function by the NPY system","volume":"162","author":"Yang","year":"2021","journal-title":"Endocrinology."},{"key":"10.1016\/j.peptides.2021.170683_bib0510","doi-asserted-by":"crossref","first-page":"178","DOI":"10.2337\/diab.31.2.178","article-title":"Effects of synthetic human pancreatic polypeptide, synthetic bovine pancreatic polypeptide, and the C-terminal hexapeptide on pancreatic somatostatin and glucagon secretion in the rat","volume":"31","author":"Trimble","year":"1982","journal-title":"Diabetes."},{"key":"10.1016\/j.peptides.2021.170683_bib0515","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-017-00624-2","article-title":"Inhibition of Y1 receptor signaling improves islet transplant outcome","volume":"8","author":"Loh","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.peptides.2021.170683_bib0520","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/j.1748-1716.1983.tb07316.x","article-title":"Effects of PYY and PP on endocrine pancreas","volume":"119","author":"Szec\u00f3wka","year":"1983","journal-title":"Acta Physiol. Scand."},{"key":"10.1016\/j.peptides.2021.170683_bib0525","doi-asserted-by":"crossref","DOI":"10.1152\/ajpendo.00530.2003","article-title":"Selective activation of central NPY Y1 vs. Y5 receptor elicits hyperinsulinemia via distinct mechanisms","volume":"287","author":"Gao","year":"2004","journal-title":"Am. J. Physiol. - Endocrinol. Metab."},{"key":"10.1016\/j.peptides.2021.170683_bib0530","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1053\/j.gastro.2012.04.047","article-title":"Selective ablation of peptide YY cells in adult mice reveals their role in beta cell survival","volume":"143","author":"Sam","year":"2012","journal-title":"Gastroenterology."},{"key":"10.1016\/j.peptides.2021.170683_bib0535","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/cne.21543","article-title":"Characterization of brainstem peptide YY (PYY) neurons","volume":"506","author":"Glavas","year":"2008","journal-title":"J. Comp. Neurol."},{"key":"10.1016\/j.peptides.2021.170683_bib0540","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/0167-0115(94)90204-6","article-title":"Two molecular forms of Peptide YY (PYY) are abundant in human blood: characterization of a radioimmunoassay recognizing PYY 1-36 and PYY 3-36","volume":"51","author":"Grandt","year":"1994","journal-title":"Regul. Pept."},{"key":"10.1016\/j.peptides.2021.170683_bib0545","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.coph.2004.06.007","article-title":"Peptide YY and appetite control","volume":"4","author":"McGowan","year":"2004","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.peptides.2021.170683_bib0550","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/nrgastro.2012.185","article-title":"Ghrelin, the proglucagon-derived peptides and peptide YY in nutrient homeostasis","volume":"9","author":"Dong","year":"2012","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.peptides.2021.170683_bib0555","doi-asserted-by":"crossref","DOI":"10.1152\/ajpregu.00726.2005","article-title":"PYY(3-36) reduces food intake and body weight and improves insulin sensitivity in rodent models of diet-induced obesity","volume":"291","author":"Vrang","year":"2006","journal-title":"Am. J. Physiol. - Regul. Integr. Comp. Physiol."},{"key":"10.1016\/j.peptides.2021.170683_bib0560","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/nature00887","article-title":"Gut hormone PYY3-36 physiologically inhibits food intake","volume":"418","author":"Batterham","year":"2002","journal-title":"Nature."},{"key":"10.1016\/j.peptides.2021.170683_bib0565","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1210\/jc.2017-00469","article-title":"The effect of a subcutaneous infusion of GLP-1, OXM, and PYY on energy intake and expenditure in obese volunteers","volume":"102","author":"Tan","year":"2017","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.peptides.2021.170683_bib0570","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.brainres.2005.02.065","article-title":"Blockade of the neuropeptide Y Y2 receptor with the specific antagonist BIIE0246 attenuates the effect of endogenous and exogenous peptide YY (3-36) on food intake","volume":"1043","author":"Abbott","year":"2005","journal-title":"Brain Res."},{"key":"10.1016\/j.peptides.2021.170683_bib0575","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1007\/s00125-014-3292-y","article-title":"More than just an appetite regulator","volume":"57","author":"Persaud","year":"2014","journal-title":"Diabetologia."},{"key":"10.1016\/j.peptides.2021.170683_bib0580","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.pharmthera.2013.05.004","article-title":"An atlas and functional analysis of G-protein coupled receptors in human islets of Langerhans","volume":"139","author":"Amisten","year":"2013","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.peptides.2021.170683_bib0585","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.molmet.2013.03.001","article-title":"Peripheral activation of the Y2-receptor promotes secretion of GLP-1 and improves glucose tolerance","volume":"2","author":"Chandarana","year":"2013","journal-title":"Mol. Metab."},{"key":"10.1016\/j.peptides.2021.170683_bib0590","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1007\/BF00400941","article-title":"Mechanisms underlying the insulinostatic effect of peptide YY in mouse pancreatic islets","volume":"37","author":"Nieuwenhuizen","year":"1994","journal-title":"Diabetologia."},{"key":"10.1016\/j.peptides.2021.170683_bib0595","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1097\/00006676-199209000-00013","article-title":"Evidence for a direct inhibitory effect of pyy on insulin secretion in rats","volume":"7","author":"Bertrand","year":"1992","journal-title":"Pancreas."},{"key":"10.1016\/j.peptides.2021.170683_bib0600","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1007\/s00125-006-0237-0","article-title":"Peptide YY ablation in mice leads to the development of hyperinsulinaemia and obesity","volume":"49","author":"Boey","year":"2006","journal-title":"Diabetologia."},{"key":"10.1016\/j.peptides.2021.170683_bib0605","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1038\/ijo.2008.24","article-title":"Abnormal postprandial PYY response in insulin sensitive nondiabetic subjects with a strong family history of type 2 diabetes","volume":"32","author":"Viardot","year":"2008","journal-title":"Int. J. Obes."},{"key":"10.1016\/j.peptides.2021.170683_bib0610","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1056\/NEJMoa030204","article-title":"Inhibition of Food Intake in Obese Subjects by Peptide YY 3\u201336","volume":"349","author":"Batterham","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.peptides.2021.170683_bib0615","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.coph.2013.09.014","article-title":"Enteroendocrine secretion of gut hormones in diabetes, obesity and after bariatric surgery","volume":"13","author":"Holst","year":"2013","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.peptides.2021.170683_bib0620","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.molmet.2013.11.010","article-title":"Effects of Roux-en-Y gastric bypass on energy and glucose homeostasis are preserved in two mouse models of functional glucagon-like peptide-1 deficiency","volume":"3","author":"Mokadem","year":"2014","journal-title":"Mol. Metab."},{"key":"10.1016\/j.peptides.2021.170683_bib0625","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.2337\/db12-1498","article-title":"Vertical sleeve gastrectomy is effective in two genetic mouse models of glucagon-like peptide 1 receptor deficiency","volume":"62","author":"Wilson-P\u00e9rez","year":"2013","journal-title":"Diabetes."},{"key":"10.1016\/j.peptides.2021.170683_bib0630","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.tem.2017.04.005","article-title":"The role of PYY in pancreatic islet physiology and surgical control of diabetes","volume":"28","author":"Guida","year":"2017","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.peptides.2021.170683_bib0635","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1210\/en.2015-1168","article-title":"Pancreatic PYY is critical in the control of insulin secretion and glucose homeostasis in female mice","volume":"156","author":"Shi","year":"2015","journal-title":"Endocrinology."},{"key":"10.1016\/j.peptides.2021.170683_bib0640","doi-asserted-by":"crossref","DOI":"10.1177\/1179551419855626","article-title":"Effects of 2 novel PYY(1-36) analogues, (P3L31P34)PYY(1-36) and PYY(1-36)(Lys12PAL), on pancreatic beta-cell function, growth, and survival","volume":"12","author":"Lafferty","year":"2019","journal-title":"Clin. Med. Insights Endocrinol. Diabetes"},{"key":"10.1016\/j.peptides.2021.170683_bib0645","doi-asserted-by":"crossref","first-page":"10519","DOI":"10.1021\/acs.jmedchem.8b01046","article-title":"Design of Y 2 receptor selective and proteolytically stable PYY 3-36 analogues","volume":"61","author":"\u00d8stergaard","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.peptides.2021.170683_bib0650","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1210\/jc.2006-1806","article-title":"Efficacy and safety of intranasal peptide YY3-36 for weight reduction in obese adults","volume":"92","author":"Gantz","year":"2007","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.peptides.2021.170683_bib0655","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1210\/en.2019-00100","article-title":"Modified peptide YY molecule attenuates the activity of NPY\/AgRP neurons and reduces food intake in male mice","volume":"160","author":"Jones","year":"2019","journal-title":"Endocrinology"},{"key":"10.1016\/j.peptides.2021.170683_bib0660","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.cmet.2019.01.017","article-title":"A long-acting PYY 3\u201336 analog mediates robust anorectic efficacy with minimal Emesis in nonhuman Primates","volume":"29","author":"Rangwala","year":"2019","journal-title":"Cell Metab."},{"key":"10.1016\/j.peptides.2021.170683_bib0665","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.3389\/fendo.2020.617400","article-title":"Amylin and Calcitonin: Potential Therapeutic Strategies to Reduce Body Weight and Liver Fat","volume":"11","author":"Mathiesen","year":"2021","journal-title":"Front. Endocrinol. (Lausanne)."},{"key":"10.1016\/j.peptides.2021.170683_bib0670","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1172\/JCI109636","article-title":"Regulation of calcitonin secretion in normal man by changes of serum calcium within the physiologic range","volume":"64","author":"Austin","year":"1979","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.peptides.2021.170683_bib0675","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1046\/j.1365-2613.2000.00176.x","article-title":"Calcitonin and calcitonin receptors: bone and beyond","volume":"81","author":"Pondel","year":"2000","journal-title":"Int. J. Exp. Pathol."},{"key":"10.1016\/j.peptides.2021.170683_bib0680","first-page":"551","article-title":"A recombinant calcitonin receptor independently stimulates 3\u2019,5\u2019-cyclic adenosine monophosphate and ca2+\/inositol phosphate signaling pathways","volume":"6","author":"Chabre","year":"1992","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.peptides.2021.170683_bib0685","article-title":"A cloned porcine renal calcitonin receptor couples to adenylyl cyclase and phospholipase C","volume":"262","author":"Force","year":"1992","journal-title":"Am. J. Physiol. - Ren. Fluid Electrolyte Physiol."},{"key":"10.1016\/j.peptides.2021.170683_bib0690","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.1210\/endo.139.7.6112","article-title":"Phospholipase D- and protein kinase C isoenzyme-dependent signal transduction pathways activated by the calcitonin receptor","volume":"139","author":"Naro","year":"1998","journal-title":"Endocrinology."},{"key":"10.1016\/j.peptides.2021.170683_bib0695","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/bph.14075","article-title":"Update on the pharmacology of calcitonin\/CGRP family of peptides: IUPHAR Review 25","volume":"175","author":"Hay","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.peptides.2021.170683_bib0700","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1002\/jbmr.1869","article-title":"Calcitonin: Physiology or fantasy?","volume":"28","author":"Davey","year":"2013","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.peptides.2021.170683_bib0705","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1056\/NEJM198708273170904","article-title":"Axial and appendicular bone mineral density in patients with long-term deficiency or excess of calcitonin","volume":"317","author":"Hurley","year":"1987","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.peptides.2021.170683_bib0710","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0092042","article-title":"Prolonged calcitonin receptor signaling by salmon, but not human calcitonin, reveals ligand bias","volume":"9","author":"Andreassen","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.peptides.2021.170683_bib0715","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/0091-3057(80)90196-3","article-title":"Calcitonin reduces feeding in man, monkey and rat","volume":"12","author":"Perlow","year":"1980","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.peptides.2021.170683_bib0720","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1126\/science.493987","article-title":"Calcitonin: inhibitory effect on eating in rats","volume":"206","author":"Freed","year":"1979","journal-title":"Science (80-.)"},{"key":"10.1016\/j.peptides.2021.170683_bib0725","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/S0140-6736(77)91908-0","article-title":"Hyperglyc\u00e6mic effect of synthetic salmon calcitonin","volume":"310","author":"Gattereau","year":"1977","journal-title":"Lancet"},{"key":"10.1016\/j.peptides.2021.170683_bib0730","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/S0140-6736(78)90532-9","article-title":"Hyperglyc\u00e6mic effect of synthetic salmon calcitonin","volume":"311","author":"Evans","year":"1978","journal-title":"Lancet."},{"key":"10.1016\/j.peptides.2021.170683_bib0735","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1210\/jcem-53-2-318","article-title":"Calcitonin, a diabetogenic hormone?","volume":"53","author":"Passariello","year":"1981","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.peptides.2021.170683_bib0740","article-title":"Calcitonin modulation of insulin and glucagon secretion in man","volume":"5","author":"Giugliano","year":"1982","journal-title":"Am. J. Physiol. - Endocrinol. Metab."},{"key":"10.1016\/j.peptides.2021.170683_bib0745","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1124\/pr.115.010629","article-title":"Amylin: pharmacology, physiology, and clinical potential","volume":"67","author":"Hay","year":"2015","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.peptides.2021.170683_bib0750","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1210\/endo.140.6.6930","article-title":"An amylin receptor is revealed following co-transfection of a calcitonin receptor with receptor activity modifying proteins-1 or -3","volume":"140","author":"Muff","year":"1999","journal-title":"Endocrinology"},{"key":"10.1016\/j.peptides.2021.170683_bib0755","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.2337\/diabetes.54.4.1100","article-title":"The role of amylin and glucagon in the dampening of glycemic excursions in children with type 1 diabetes","volume":"54","author":"Heptulla","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.peptides.2021.170683_bib0760","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/0167-0115(90)90192-Y","article-title":"Inhibitory effect of rat amylin on the insulin responses to glucose and arginine in the perfused rat pancreas","volume":"31","author":"Silvestre","year":"1990","journal-title":"Regul. Pept."},{"key":"10.1016\/j.peptides.2021.170683_bib0765","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0167-0115(02)00252-5","article-title":"Islet amyloid polypeptide inhibits glucagon release and exerts a dual action on insulin release from isolated islets","volume":"111","author":"\u00c5kesson","year":"2003","journal-title":"Regul. Pept."},{"key":"10.1016\/j.peptides.2021.170683_bib0770","doi-asserted-by":"crossref","DOI":"10.1152\/ajpendo.2001.280.3.E443","article-title":"Selective amylin inhibition of the glucagon response to arginine is extrinsic to the pancreas","volume":"280","author":"Silvestre","year":"2001","journal-title":"Am. J. Physiol. - Endocrinol. Metab."},{"key":"10.1016\/j.peptides.2021.170683_bib0775","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0026-0495(97)90170-0","article-title":"Dose-response for glucagonostatic effect of amylin in rats","volume":"46","author":"Gedulin","year":"1997","journal-title":"Metabolism."},{"key":"10.1016\/j.peptides.2021.170683_bib0780","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/0168-8227(92)90142-E","article-title":"Homologous islet amyloid polypeptide: effects on plasma levels of glucagon, insulin and glucose in the mouse","volume":"18","author":"Panagiotidis","year":"1992","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.peptides.2021.170683_bib0785","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1210\/jc.2009-2133","article-title":"Do the actions of glucagon-like peptide-1 on gastric emptying, appetite, and food intake involve release of amylin in humans?","volume":"95","author":"Asmar","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.peptides.2021.170683_bib0790","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/BF00401050","article-title":"Failure to establish islet amyloid polypeptide (amylin) as a circulating beta cell inhibiting hormone in man","volume":"33","author":"Bretherton-Watt","year":"1990","journal-title":"Diabetologia."},{"key":"10.1016\/j.peptides.2021.170683_bib0795","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2337\/diacare.26.1.1","article-title":"Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglyceride excursions among patients with type 1 diabetes intensively treated with insulin pumps","volume":"26","author":"Levetan","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.peptides.2021.170683_bib0800","first-page":"1439","article-title":"Pramlintide and the treatment of diabetes: a review of the data since its introduction, Expert Opin","volume":"12","author":"Younk","year":"2011","journal-title":"Pharmacother."},{"key":"10.1016\/j.peptides.2021.170683_bib0805","first-page":"317","article-title":"Amylin-based pharmacotherapy-past, present & future","volume":"8","author":"Roth","year":"2008","journal-title":"Agents Med. Chem."},{"key":"10.1016\/j.peptides.2021.170683_bib0810","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/s41551-020-0555-4","article-title":"A co-formulation of supramolecularly stabilized insulin and pramlintide enhances mealtime glucagon suppression in diabetic pigs","volume":"4","author":"Maikawa","year":"2020","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.peptides.2021.170683_bib0815","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/ijo.2009.238","article-title":"Davalintide (AC2307), a novel amylin-mimetic peptide: Enhanced pharmacological properties over native amylin to reduce food intake and body weight","volume":"34","author":"MacK","year":"2010","journal-title":"Int. J. Obes."},{"key":"10.1016\/j.peptides.2021.170683_bib0820","doi-asserted-by":"crossref","DOI":"10.1186\/s12902-020-00678-2","article-title":"The dual amylin and calcitonin receptor agonist KBP-089 and the GLP-1 receptor agonist liraglutide act complimentarily on body weight reduction and metabolic profile","volume":"21","author":"Larsen","year":"2021","journal-title":"BMC Endocr. Disord."},{"key":"10.1016\/j.peptides.2021.170683_bib0825","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/bph.13723","article-title":"A novel dual amylin and calcitonin receptor agonist, KBP-089, induces weight loss through a reduction in fat, but not lean mass, while improving food preference","volume":"174","author":"Gydesen","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.peptides.2021.170683_bib0830","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1016\/S0140-6736(21)00845-X","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2\u00b74 mg for weight management: a randomised, controlled, phase 1b trial","volume":"397","author":"Enebo","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.peptides.2021.170683_bib0835","unstructured":"Skarbaliene J., Pagler T., Eickelmann P., Just R., Anti-obesity effects of the novel long-acting amylin analogue ZP4982 in high-fat diet fed rats, New Orleans: American Diabetes Association\u2019s (ADA) 76th Scientific Sessions. Available at: https:\/\/www.zealandpharma.com\/publications-amylin."},{"key":"10.1016\/j.peptides.2021.170683_bib0840","unstructured":"Skarbaliene J., Just R., Anti-diabetic effects of novel long-acting amylin analogues ZP4982 and ZP5461 in ZDF rats, New Orleans: American Diabetes Association\u2019s (ADA) 76th Scientific Sessions. Available at: https:\/\/ www.zealandpharma.com\/publications-amylin."},{"key":"10.1016\/j.peptides.2021.170683_bib0845","doi-asserted-by":"crossref","DOI":"10.1210\/endo-123-4-2009","article-title":"Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach","author":"\u00d8rskov","year":"1988","journal-title":"Endocrinology"},{"key":"10.1016\/j.peptides.2021.170683_bib0850","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s00125-005-0098-y","article-title":"The metabolite generated by dipeptidyl-peptidase 4 metabolism of glucagon-like peptide-1 has no influence on plasma glucose levels in patients with type 2 diabetes","volume":"49","author":"Zander","year":"2006","journal-title":"Diabetologia."},{"key":"10.1016\/j.peptides.2021.170683_bib0855","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1007\/s00125-011-2168-7","article-title":"Dipeptidyl peptidase-4 inhibition increases portal concentrations of intact glucagon-like peptide-1 (GLP-1) to a greater extent than peripheral concentrations in anaesthetised pigs","volume":"54","author":"Hj\u00f8llund","year":"2011","journal-title":"Diabetologia."},{"key":"10.1016\/j.peptides.2021.170683_bib0860","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1530\/JOE-11-0094","article-title":"Processing of proglucagon to GLP-1 in pancreatic \u03b1-cells: Is this a paracrine mechanism enabling GLP-1 to act on \u03b2-cells?","volume":"211","author":"Whalley","year":"2011","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.peptides.2021.170683_bib0865","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/j.celrep.2018.10.018","article-title":"Insulin secretion depends on intra-islet glucagon signaling","volume":"25","author":"Svendsen","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.peptides.2021.170683_bib0870","doi-asserted-by":"crossref","first-page":"34","DOI":"10.2337\/db18-0317","article-title":"GLP-1 receptor in pancreatic A-cells regulates glucagon secretion in a glucose-dependent bidirectional manner","volume":"68","author":"Zhang","year":"2019","journal-title":"Diabetes."},{"key":"10.1016\/j.peptides.2021.170683_bib0875","doi-asserted-by":"crossref","DOI":"10.2337\/diab.45.2.257","article-title":"Expression and functional activity of glucagon, glucagon-like peptide I, and glucose-dependent insulinotropic peptide receptors in rat pancreatic islet cells","author":"Moens","year":"1996","journal-title":"Diabetes"},{"key":"10.1016\/j.peptides.2021.170683_bib0880","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.cmet.2016.08.020","article-title":"Single-cell transcriptome profiling of human pancreatic islets in health and type 2 diabetes","volume":"24","author":"Segerstolpe","year":"2016","journal-title":"Cell Metab."},{"key":"10.1016\/j.peptides.2021.170683_bib0885","doi-asserted-by":"crossref","first-page":"785","DOI":"10.2337\/diab.46.5.785","article-title":"Insulinotropic glucagon-like peptide I receptor expression in Glucagon-Producing -Cells of the rat endocrine pancreas","volume":"46","author":"Heller","year":"1997","journal-title":"Diabetes."},{"key":"10.1016\/j.peptides.2021.170683_bib0890","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.cmet.2010.04.007","article-title":"GLP-1 inhibits and adrenaline stimulates glucagon release by differential modulation of N- and L-type Ca2+ channel-dependent exocytosis","volume":"11","author":"De Marinis","year":"2010","journal-title":"Cell Metab."},{"key":"10.1016\/j.peptides.2021.170683_bib0895","doi-asserted-by":"crossref","DOI":"10.14814\/phy2.13852","article-title":"GLP-1 suppresses glucagon secretion in human pancreatic alpha-cells by inhibition of P\/Q-type Ca 2+ channels","volume":"6","author":"Ramracheya","year":"2018","journal-title":"Physiol. Rep."},{"key":"10.1016\/j.peptides.2021.170683_bib0900","article-title":"Using a reporter mouse to map known and novel sites of GLP-1 receptor expression in peripheral tissues of male mice","volume":"162","author":"Andersen","year":"2021","journal-title":"Endocrinol. (United States)."},{"key":"10.1016\/j.peptides.2021.170683_bib0905","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1210\/en.2017-00812","article-title":"Characterization of the glucagonlike peptide-1 receptor in male mouse brain using a novel antibody and in situ hybridization","volume":"159","author":"Jensen","year":"2018","journal-title":"Endocrinology."},{"key":"10.1016\/j.peptides.2021.170683_bib0910","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2337\/db08-0792","article-title":"Somatostatin secreted by islet \u03b4-cells fulfills multiple roles as a paracrine regulator of islet function","volume":"58","author":"Hauge-Evans","year":"2009","journal-title":"Diabetes."},{"key":"10.1016\/j.peptides.2021.170683_bib0915","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/modpathol.2014.113","article-title":"Glucagon-like-peptide-1 receptor expression in normal and diseased human thyroid and pancreas","volume":"28","author":"Waser","year":"2015","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.peptides.2021.170683_bib0920","article-title":"Glucagon-like peptide I and glucose-dependent insulinotropic polypeptide stimulate Ca2+-induced secretion in rat \u03b1-cells by a protein kinase A- mediated mechanism","author":"Ding","year":"1997","journal-title":"Diabetes"},{"key":"10.1016\/j.peptides.2021.170683_bib0925","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1007\/s00125-008-1149-y","article-title":"Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, inhibits glucagon secretion via somatostatin (receptor subtype 2) in the perfused rat pancreas","volume":"51","author":"De Heer","year":"2008","journal-title":"Diabetologia."},{"key":"10.1016\/j.peptides.2021.170683_bib0930","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/0026-0495(80)90194-8","article-title":"Selective effect of some somatostatin analogs on glucagon as opposed to insulin release in rats in vivo","volume":"29","author":"Lins","year":"1980","journal-title":"Metabolism."},{"key":"10.1016\/j.peptides.2021.170683_bib0935","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/BF00265096","article-title":"Sensitivity of rat pancreatic A and B cells to somatostatin","volume":"32","author":"Schuit","year":"1989","journal-title":"Diabetologia."},{"key":"10.1016\/j.peptides.2021.170683_bib0940","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1007\/s00125-017-4315-2","article-title":"The role of somatostatin in GLP-1-induced inhibition of glucagon secretion in mice","volume":"60","author":"\u00d8rgaard","year":"2017","journal-title":"Diabetologia."},{"key":"10.1016\/j.peptides.2021.170683_bib0945","article-title":"Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo","author":"Deacon","year":"1995","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.peptides.2021.170683_bib0950","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0014-2999(96)00795-9","article-title":"Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor","volume":"318","author":"Knudsen","year":"1996","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.peptides.2021.170683_bib0955","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s00125-005-0098-y","article-title":"The metabolite generated by dipeptidyl-peptidase 4 metabolism of glucagon-like peptide-1 has no influence on plasma glucose levels in patients with type 2 diabetes","volume":"49","author":"Zander","year":"2006","journal-title":"Diabetologia."},{"key":"10.1016\/j.peptides.2021.170683_bib0960","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1210\/jc.2002-021479","article-title":"Effects of GLP-1-(7-36)NH2, GLP-1-(7-37), and GLP-1-(9-36)NH2 on intravenous glucose tolerance and glucose-induced insulin secretion in healthy humans","volume":"88","author":"Vahl","year":"2003","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.peptides.2021.170683_bib0965","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1152\/ajpendo.00576.2005","article-title":"The glucagon-like peptide-1 metabolite GLP-1-(9-36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans","volume":"290","author":"Meier","year":"2006","journal-title":"Am. J. Physiol. - Endocrinol. Metab."},{"key":"10.1016\/j.peptides.2021.170683_bib0970","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.2337\/db09-1414","article-title":"The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action","volume":"59","author":"Hare","year":"2010","journal-title":"Diabetes."},{"key":"10.1016\/j.peptides.2021.170683_bib0975","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.2337\/diabetes.53.9.2397","article-title":"Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia","volume":"53","author":"Degn","year":"2004","journal-title":"Diabetes."},{"key":"10.1016\/j.peptides.2021.170683_bib0980","doi-asserted-by":"crossref","first-page":"424","DOI":"10.2337\/diabetes.51.2.424","article-title":"Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes","volume":"51","author":"Juhl","year":"2002","journal-title":"Diabetes."},{"key":"10.1016\/j.peptides.2021.170683_bib0985","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1185\/03007990802418851","article-title":"Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study","volume":"24","author":"DeFronzo","year":"2008","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.peptides.2021.170683_bib0990","doi-asserted-by":"crossref","first-page":"4612","DOI":"10.1210\/jc.2006-1009","article-title":"Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes","volume":"91","author":"Herman","year":"2006","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.peptides.2021.170683_bib0995","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/S1091-255X(98)80005-X","article-title":"Glucagon-like peptide 2 is a potent growth factor for small intestine and Colon","volume":"2","author":"Litvak","year":"1998","journal-title":"J. Gastrointest. Surg."},{"key":"10.1016\/j.peptides.2021.170683_bib1000","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1053\/j.gastro.2005.02.033","article-title":"Mucosal adaptation to enteral nutrients is dependent on the physiologic actions of glucagon-like peptide-2 in mice","volume":"128","author":"Shin","year":"2005","journal-title":"Gastroenterology."},{"key":"10.1016\/j.peptides.2021.170683_bib1005","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0198046","article-title":"Endogenous glucagon-like peptide- 1 and 2 are essential for regeneration after acute intestinal injury in mice","volume":"13","author":"Hytting-Andreasen","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.peptides.2021.170683_bib1010","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1097\/MPG.0000000000002899","article-title":"Experience with teduglutide in pediatric short bowel syndrome: first real-life data","volume":"71","author":"Ramos Boluda","year":"2020","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"10.1016\/j.peptides.2021.170683_bib1015","doi-asserted-by":"crossref","first-page":"18827","DOI":"10.1016\/S0021-9258(17)32241-X","article-title":"Proglucagon processing in porcine and human pancreas","volume":"269","author":"Holst","year":"1994","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.peptides.2021.170683_bib1020","doi-asserted-by":"crossref","first-page":"817","DOI":"10.3389\/fendo.2021.697120","article-title":"GLP-2 is locally produced from human islets and balances inflammation through an inter-islet-Immune cell crosstalk","volume":"12","author":"He","year":"2021","journal-title":"Front. Endocrinol. (Lausanne)."},{"key":"10.1016\/j.peptides.2021.170683_bib1025","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1053\/j.gastro.2005.10.004","article-title":"Glucagon-like peptide 2 stimulates glucagon secretion, enhances lipid absorption, and inhibits gastric acid secretion in humans","volume":"130","author":"Meier","year":"2006","journal-title":"Gastroenterology."},{"key":"10.1016\/j.peptides.2021.170683_bib1030","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/sj.ijo.0802247","article-title":"No effect of physiological concentrations of glucagon-like peptide-2 on appetite and energy intake in normal weight subjects","volume":"27","author":"S\u00f8rensen","year":"2003","journal-title":"Int. J. Obes."},{"key":"10.1016\/j.peptides.2021.170683_bib1035","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1007\/s00125-007-0761-6","article-title":"The alpha cell expresses glucagon-like peptide-2 receptors and glucagon-like peptide-2 stimulates glucagon secretion from the rat pancreas","volume":"50","author":"De Heer","year":"2007","journal-title":"Diabetologia."},{"key":"10.1016\/j.peptides.2021.170683_bib1040","first-page":"2884","article-title":"In vivo and in vitro degradation of glucagon-like Peptide-2 in Humans1","volume":"85","author":"Hartmann","year":"2000","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.peptides.2021.170683_bib1045","doi-asserted-by":"crossref","DOI":"10.1152\/ajpendo.1996.271.3.E458","article-title":"Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig","volume":"271","author":"Deacon","year":"1996","journal-title":"Am. J. Physiol. - Endocrinol. Metab."},{"key":"10.1016\/j.peptides.2021.170683_bib1050","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.regpep.2010.05.004","article-title":"Glucagon-like peptide-2, but not glucose-dependent insulinotropic polypeptide, stimulates glucagon release in patients with type 1 diabetes","volume":"163","author":"Christensen","year":"2010","journal-title":"Regul. Pept."},{"key":"10.1016\/j.peptides.2021.170683_bib1055","doi-asserted-by":"crossref","DOI":"10.14309\/ctg.0000000000000257","article-title":"Glucagon-like peptide 2 inhibits postprandial gallbladder emptying in man: a randomized, double-blinded, crossover study","volume":"11","author":"Hansen","year":"2020","journal-title":"Clin. Transl. Gastroenterol."},{"key":"10.1016\/j.peptides.2021.170683_bib1060","doi-asserted-by":"crossref","DOI":"10.1152\/ajpgi.00282.2010","article-title":"Role of cholinergic neurons in the motor effects of glucagon-like peptide-2 in mouse colon","volume":"299","author":"Amato","year":"2010","journal-title":"Am. J. Physiol. - Gastrointest. Liver Physiol."},{"key":"10.1016\/j.peptides.2021.170683_bib1065","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1210\/endo-119-4-1467","article-title":"Glucagon-like peptides GLP-1 and GLP-2, predicted products of the glucagon gene, are secreted separately from pig small intestine but not pancreas","volume":"119","author":"\u00d8rskov","year":"1986","journal-title":"Endocrinology."},{"key":"10.1016\/j.peptides.2021.170683_bib1070","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/BF00252412","article-title":"Glucagon-related peptides in the human gastrointestinal mucosa","volume":"26","author":"Baldissera","year":"1984","journal-title":"Diabetologia."},{"key":"10.1016\/j.peptides.2021.170683_bib1075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0014-5793(85)80178-2","article-title":"Glicentin is present in the pig pancreas","volume":"179","author":"Sheikh","year":"1985","journal-title":"FEBS Lett."},{"key":"10.1016\/j.peptides.2021.170683_bib1080","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.peptides.2017.09.018","article-title":"Oxyntomodulin: Actions and role in diabetes","volume":"100","author":"Holst","year":"2018","journal-title":"Peptides."},{"key":"10.1016\/j.peptides.2021.170683_bib1085","series-title":"Oxyntomodulin and Its Related Peptides","first-page":"327","author":"Bataille","year":"1996"},{"key":"10.1016\/j.peptides.2021.170683_bib1090","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1210\/endo.133.2.8102095","article-title":"Glucagon-like peptide-1-(7-36)amide, oxyntomodulin, and glucagon interact with a common receptor in a somatostatin-secreting cell line","volume":"133","author":"Gros","year":"1993","journal-title":"Endocrinology."},{"key":"10.1016\/j.peptides.2021.170683_bib1095","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1053\/j.gastro.2004.04.063","article-title":"Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure","volume":"127","author":"Baggio","year":"2004","journal-title":"Gastroenterology."},{"key":"10.1016\/j.peptides.2021.170683_bib1100","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/0167-0115(88)90099-7","article-title":"Oxyntomodulin (glicentin-(33-69)): pharmacokinetics, binding to liver cell membranes, effects on isolated perfused pig pancreas, and secretion from isolated perfused lower small intestine of pigs","volume":"21","author":"Baldissera","year":"1988","journal-title":"Regul. Pept."},{"key":"10.1016\/j.peptides.2021.170683_bib1105","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1210\/jc.2015-2335","article-title":"Effect of oxyntomodulin, glucagon, GLP-1, and combined glucagon +GLP-1 infusion on food intake, appetite, and resting energy expenditure","volume":"100","author":"Bagger","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.peptides.2021.170683_bib1110","doi-asserted-by":"crossref","DOI":"10.1152\/ajpendo.00576.2007","article-title":"Oxyntomodulin ameliorates glucose intolerance in mice fed a high-fat diet","volume":"294","author":"Parlevliet","year":"2008","journal-title":"Am. J. Physiol. - Endocrinol. Metab."},{"key":"10.1016\/j.peptides.2021.170683_bib1115","doi-asserted-by":"crossref","first-page":"5670","DOI":"10.1210\/en.2008-0336","article-title":"The glucagon-like peptide-1 receptor agonist oxyntomodulin enhances \u03b2-cell function but does not inhibit gastric emptying in mice","volume":"149","author":"Maida","year":"2008","journal-title":"Endocrinology."},{"key":"10.1016\/j.peptides.2021.170683_bib1120","doi-asserted-by":"crossref","first-page":"22418","DOI":"10.1074\/jbc.M212355200","article-title":"The role of dipeptidyl peptidase IV in the cleavage of glucagon family peptides: In vivo metabolism of pituitary adenylate cyclase-activating polypeptide-(1-38)","volume":"278","author":"Zhu","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.peptides.2021.170683_bib1125","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ebiom.2016.03.034","article-title":"Oxyntomodulin identified as a marker of type 2 diabetes and gastric bypass surgery by mass-spectrometry based profiling of human plasma","volume":"7","author":"Wewer Albrechtsen","year":"2016","journal-title":"EBioMedicine."},{"key":"10.1016\/j.peptides.2021.170683_bib1130","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1210\/jc.2017-00469","article-title":"The effect of a subcutaneous infusion of GLP-1, OXM, and PYY on energy intake and expenditure in obese volunteers","volume":"102","author":"Tan","year":"2017","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.peptides.2021.170683_bib1135","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1002\/hep.28962","article-title":"A novel glucagon-like peptide 1\/glucagon receptor dual agonist improves steatohepatitis and liver regeneration in mice","volume":"65","author":"Valdecantos","year":"2017","journal-title":"Hepatology."},{"key":"10.1016\/j.peptides.2021.170683_bib1140","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.2337\/diabetes.54.8.2390","article-title":"Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial","volume":"54","author":"Wynne","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.peptides.2021.170683_bib1145","doi-asserted-by":"crossref","first-page":"7064","DOI":"10.1016\/j.bmc.2013.09.016","article-title":"A PEGylated analog of the gut hormone oxyntomodulin with long-lasting antihyperglycemic, insulinotropic and anorexigenic activity","volume":"21","author":"Bianchi","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.peptides.2021.170683_bib1150","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1038\/ijo.2010.110","article-title":"Subcutaneous oxyntomodulin analogue administration reduces body weight in lean and obese rodents","volume":"34","author":"Liu","year":"2010","journal-title":"Int. J. Obes."},{"key":"10.1016\/j.peptides.2021.170683_bib1155","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1080\/14728214.2021.1947240","article-title":"Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity","volume":"26","author":"Jepsen","year":"2021","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"10.1016\/j.peptides.2021.170683_bib1160","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.2337\/dc20-2151","article-title":"Effects of cotadutide on metabolic and hepatic parameters in adults with overweight or obesity and type 2 diabetes: a 54-week randomized phase 2b study","volume":"44","author":"Nahra","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.peptides.2021.170683_bib1165","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1111\/dom.14394","article-title":"Improved postprandial glucose metabolism in type 2 diabetes by the dual glucagon-like peptide-1\/glucagon receptor agonist SAR425899 in comparison with liraglutide","volume":"23","author":"Schiavon","year":"2021","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.peptides.2021.170683_bib1170","series-title":"A Study to Assess the Safety and Efficacy of SAR425899 in Patients With Type 2 Diabetes Mellitus","author":"Nct","year":"2016"},{"key":"10.1016\/j.peptides.2021.170683_bib1175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-020-73815-5","article-title":"Receptor occupancy of dual glucagon-like peptide 1\/glucagon receptor agonist SAR425899 in individuals with type 2 diabetes","volume":"10","author":"Eriksson","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.peptides.2021.170683_bib1180","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0167-0115(02)00039-3","article-title":"Gastric inhibitory polypeptide: the neglected incretin revisited","volume":"107","author":"Meier","year":"2002","journal-title":"Regul. Pept."},{"key":"10.1016\/j.peptides.2021.170683_bib1185","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/jdi.12478","article-title":"Mechanisms underlying glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 secretion","volume":"7","author":"Reimann","year":"2016","journal-title":"J. Diabetes Investig."},{"key":"10.1016\/j.peptides.2021.170683_bib1190","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.bcp.2017.02.012","article-title":"GIP(3\u201330)NH2 is a potent competitive antagonist of the GIP receptor and effectively inhibits GIP-mediated insulin, glucagon, and somatostatin release","volume":"131","author":"Sparre-Ulrich","year":"2017","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.peptides.2021.170683_bib1195","doi-asserted-by":"crossref","DOI":"10.1172\/JCI116186","article-title":"Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type- 2 diabetes mellitus","author":"Nauck","year":"1993","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.peptides.2021.170683_bib1200","doi-asserted-by":"crossref","DOI":"10.2337\/diab.45.2.257","article-title":"Expression and functional activity of glucagon, glucagon-like peptide I, and glucose-dependent insulinotropic peptide receptors in rat pancreatic islet cells","author":"Moens","year":"1996","journal-title":"Diabetes"},{"key":"10.1016\/j.peptides.2021.170683_bib1205","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.2337\/db08-0958","article-title":"Exogenous glucose-dependent insulinotropic polypeptide worsens postprandial hyperglycemia in type 2 diabetes","volume":"58","author":"Chia","year":"2009","journal-title":"Diabetes."},{"key":"10.1016\/j.peptides.2021.170683_bib1210","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.1073\/pnas.1602306113","article-title":"Use of the Fluidigm C1 platform for RNA sequencing of single mouse pancreatic islet cells","volume":"113","author":"Xin","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.peptides.2021.170683_bib1215","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2019.170213","article-title":"The role of GIP in \u03b1-cells and glucagon secretion","volume":"125","author":"El","year":"2020","journal-title":"Peptides."},{"key":"10.1016\/j.peptides.2021.170683_bib1220","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1007\/s00125-003-1103-y","article-title":"Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia","volume":"46","author":"Meier","year":"2003","journal-title":"Diabetologia."},{"key":"10.1016\/j.peptides.2021.170683_bib1225","doi-asserted-by":"crossref","first-page":"3103","DOI":"10.2337\/db11-0979","article-title":"Glucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans","volume":"60","author":"Christensen","year":"2011","journal-title":"Diabetes."},{"key":"10.1016\/j.peptides.2021.170683_bib1230","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1210\/endo-103-2-610","article-title":"Interaction of gastric inhibitory polypeptide, glucose, and arginine on insulin and glucagon secretion from the perfused rat pancreas","volume":"103","author":"Pederson","year":"1978","journal-title":"Endocrinology."},{"key":"10.1016\/j.peptides.2021.170683_bib1235","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1016\/S0140-6736(18)32260-8","article-title":"Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial","volume":"392","author":"Frias","year":"2018","journal-title":"Lancet."},{"key":"10.1016\/j.peptides.2021.170683_bib1240","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1016\/j.peptides.2006.03.038","article-title":"Differential processing of pro-neurotensin\/neuromedin N and relationship to pro-hormone convertases","volume":"27","author":"Kitabgi","year":"2006","journal-title":"Peptides."},{"key":"10.1016\/j.peptides.2021.170683_bib1245","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1139\/jpn.0627","article-title":"The role of neurotensin in central nervous system pathophysiology: what is the evidence?","volume":"31","author":"St.-Gelais","year":"2006","journal-title":"J. Psychiatry Neurosci."},{"key":"10.1016\/j.peptides.2021.170683_bib1250","doi-asserted-by":"crossref","first-page":"143","DOI":"10.3389\/fendo.2012.00143","article-title":"Neurotensin and its receptors in the control of glucose homeostasis","volume":"3","author":"Mazella","year":"2012","journal-title":"Front. Endocrinol. (Lausanne)."},{"key":"10.1016\/j.peptides.2021.170683_bib1255","doi-asserted-by":"crossref","DOI":"10.1210\/endo-98-3-819","article-title":"Effects of neurotensin and substance p on plasma insulin, glucagon and glucose levels","author":"Brown","year":"1976","journal-title":"Endocrinology"},{"key":"10.1016\/j.peptides.2021.170683_bib1260","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1210\/endo-105-1-256","article-title":"Effect of neurotensin on insulin, glucagon, and somatostatin release from isolated pancreatic islets","volume":"105","author":"Dolais-Kitabgi","year":"1979","journal-title":"Endocrinology."},{"key":"10.1016\/j.peptides.2021.170683_bib1265","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1210\/endo-102-2-393","article-title":"Effects of substance p and neurotensin infused intrapancreatically on glucagon and insulin secretion","volume":"102","author":"Kaneto","year":"1978","journal-title":"Endocrinology."},{"key":"10.1016\/j.peptides.2021.170683_bib1270","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/0026-0495(81)90063-9","article-title":"Immunoreactive neurotensin levels in pancreas: elevation in diabetic rats and mice","volume":"30","author":"Fernstrom","year":"1981","journal-title":"Metabolism."},{"key":"10.1016\/j.peptides.2021.170683_bib1275","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/0167-0115(86)90207-7","article-title":"Neurotensin in diabetes and obesity","volume":"14","author":"Service","year":"1986","journal-title":"Regul. Pept."},{"key":"10.1016\/j.peptides.2021.170683_bib1280","doi-asserted-by":"crossref","first-page":"3482","DOI":"10.1210\/en.2016-1329","article-title":"Effects of peripheral neurotensin on appetite regulation and its role in gastric bypass surgery","volume":"157","author":"Ratner","year":"2016","journal-title":"Endocrinology."},{"key":"10.1016\/j.peptides.2021.170683_bib1285","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/nature17662","article-title":"An obligatory role for neurotensin in high-fat-diet-induced obesity","volume":"533","author":"Li","year":"2016","journal-title":"Nature."},{"key":"10.1016\/j.peptides.2021.170683_bib1290","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.2337\/db18-1009","article-title":"Long-acting neurotensin synergizes with liraglutide to reverse obesity through a melanocortin-dependent pathway","volume":"68","author":"Ratner","year":"2019","journal-title":"Diabetes."},{"key":"10.1016\/j.peptides.2021.170683_bib1295","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/45230","article-title":"Ghrelin is a growth-hormone-releasing acylated peptide from stomach","volume":"402","author":"Kojima","year":"1999","journal-title":"Nature."},{"key":"10.1016\/j.peptides.2021.170683_bib1300","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.molmet.2015.03.005","volume":"4","author":"M\u00fcller","year":"2015","journal-title":"Ghrelin, Mol. Metab."},{"key":"10.1016\/j.peptides.2021.170683_bib1305","doi-asserted-by":"crossref","first-page":"7467","DOI":"10.1073\/pnas.1002271107","article-title":"Ghrelin O-acyltransferase (GOAT) is essential for growth hormone-mediated survival of calorie-restricted mice","volume":"107","author":"Zhao","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.peptides.2021.170683_bib1310","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.molmet.2013.10.001","article-title":"Arcuate AgRP neurons mediate orexigenic and glucoregulatory actions of ghrelin","volume":"3","author":"Wang","year":"2014","journal-title":"Mol. Metab."},{"key":"10.1016\/j.peptides.2021.170683_bib1315","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1210\/me.2011-1001","article-title":"Ghrelin directly stimulates glucagon secretion from pancreatic \u03b1-cells","volume":"25","author":"Chuang","year":"2011","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.peptides.2021.170683_bib1320","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.regpep.2004.08.031","article-title":"Morphological analysis of ghrelin and its receptor distribution in the rat pancreas","volume":"126","author":"Kageyama","year":"2005","journal-title":"Regul. Pept."},{"key":"10.1016\/j.peptides.2021.170683_bib1325","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22083950","article-title":"\u0392 cell GHS-R regulates insulin secretion and sensitivity","volume":"22","author":"Pradhan","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.peptides.2021.170683_bib1330","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1530\/eje.0.1460241","article-title":"Inhibitory effect of ghrelin on insulin and pancreatic somatostatin secretion","volume":"146","author":"Egido","year":"2002","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.peptides.2021.170683_bib1335","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1007\/s00125-016-4033-1","article-title":"Transcriptomic profiling of pancreatic alpha, beta and delta cell populations identifies delta cells as a principal target for ghrelin in mouse islets","volume":"59","author":"Adriaenssens","year":"2016","journal-title":"Diabetologia."},{"key":"10.1016\/j.peptides.2021.170683_bib1340","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1210\/jc.2002-021504","article-title":"The endocrine response to ghrelin as a function of gender in humans in young and elderly subjects","volume":"88","author":"Broglio","year":"2003","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.peptides.2021.170683_bib1345","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.2337\/db10-0504","article-title":"Ghrelin suppresses glucose-stimulated insulin secretion and deteriorates glucose tolerance in healthy humans","volume":"59","author":"Tong","year":"2010","journal-title":"Diabetes."},{"key":"10.1016\/j.peptides.2021.170683_bib1350","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1210\/jc.2015-4154","article-title":"Ghrelin impairs prandial glucose tolerance and insulin secretion in healthy humans despite increasing GLP-1","volume":"101","author":"Tong","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.peptides.2021.170683_bib1355","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.numecd.2005.02.006","article-title":"Metabolic and endocrine effects of physiological increments in plasma ghrelin concentrations","volume":"15","author":"Lucidi","year":"2005","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"10.1016\/j.peptides.2021.170683_bib1360","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/bcp.13127","article-title":"Pharmacokinetics and pharmacodynamics of PF-05190457: the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects","volume":"83","author":"Denney","year":"2017","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.peptides.2021.170683_bib1365","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/45230","article-title":"Ghrelin is a growth-hormone-releasing acylated peptide from stomach","volume":"402","author":"Kojima","year":"1999","journal-title":"Nature."},{"key":"10.1016\/j.peptides.2021.170683_bib1370","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1210\/jcem.87.6.8739","article-title":"The Tissue Distribution of the mRNA of Ghrelin and Subtypes of Its Receptor, GHS-R, in Humans","volume":"87","author":"Gnanapavan","year":"2002","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.peptides.2021.170683_bib1375","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.2337\/db19-0079","article-title":"Intraislet ghrelin signaling does not regulate insulin secretion from adult mice","volume":"68","author":"Gray","year":"2019","journal-title":"Diabetes."},{"key":"10.1016\/j.peptides.2021.170683_bib1380","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.2337\/db06-0878","article-title":"Blockade of pancreatic islet-derived ghrelin enhances insulin secretion to prevent high-fat diet-induced glucose intolerance","volume":"55","author":"Dezaki","year":"2006","journal-title":"Diabetes."},{"key":"10.1016\/j.peptides.2021.170683_bib1385","doi-asserted-by":"crossref","first-page":"19003","DOI":"10.1073\/pnas.1209590109","article-title":"Modification of ghrelin receptor signaling by somatostatin receptor-5 regulates insulin release","volume":"109","author":"Park","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.peptides.2021.170683_bib1390","first-page":"432","article-title":"Mechanism of ghrelin-evoked glucagon secretion from the pancreas of diabetic rats","volume":"23","author":"Adeghate","year":"2002","journal-title":"Neuroendocrinol. Lett."},{"key":"10.1016\/j.peptides.2021.170683_bib1395","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/nrn2400","article-title":"Central mechanisms of osmosensation and systemic osmoregulation","volume":"9","author":"Bourque","year":"2008","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.peptides.2021.170683_bib1400","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1152\/physrev.00035.2011","article-title":"Vasopressin V1a and V1b receptors: from molecules to physiological systems","volume":"92","author":"aki Koshimizu","year":"2012","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.peptides.2021.170683_bib1405","first-page":"S127","article-title":"Pathophysiology of renal fluid retention, Kidney Int","volume":"54","author":"Schrier","year":"1998","journal-title":"Suppl."},{"key":"10.1016\/j.peptides.2021.170683_bib1410","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1161\/CIRCULATIONAHA.109.909663","article-title":"Plasma copeptin and the risk of diabetes mellitus","volume":"121","author":"Enh\u00f6rning","year":"2010","journal-title":"Circulation."},{"key":"10.1016\/j.peptides.2021.170683_bib1415","doi-asserted-by":"crossref","first-page":"7807","DOI":"10.1073\/pnas.0600875103","article-title":"V1a vasopressin receptors maintain normal blood pressure by regulating circulating blood volume and baroreflex sensitivity","volume":"103","author":"Koshimizu","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.peptides.2021.170683_bib1420","first-page":"137","article-title":"(3h)-vasopressin binding to isolated rat hepatocytes and liver membranes: regulation by GTP and relation to glycogen phosphorylase activation","volume":"1","author":"Cantau","year":"1980","journal-title":"J. Recept. Signal Transduct."},{"key":"10.1016\/j.peptides.2021.170683_bib1425","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/978-1-4615-4871-3_41","article-title":"Vasopressin regulates adrenal functions by acting through different vasopressin receptor subtypes","volume":"449","author":"Grazzini","year":"1998","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.peptides.2021.170683_bib1430","doi-asserted-by":"crossref","first-page":"3332","DOI":"10.1210\/JC.2015-2362","article-title":"Copeptin, insulin resistance, and risk of incident diabetes in older men","volume":"100","author":"Wannamethee","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.peptides.2021.170683_bib1435","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/ijo.2012.88","article-title":"Copeptin, a marker of vasopressin, in abdominal obesity, diabetes and microalbuminuria: The prospective Malm\u00f6 Diet and Cancer Study cardiovascular cohort","volume":"37","author":"Enh\u00f6rning","year":"2013","journal-title":"Int. J. Obes."},{"key":"10.1016\/j.peptides.2021.170683_bib1440","doi-asserted-by":"crossref","first-page":"54","DOI":"10.2337\/diab.38.1.54","article-title":"Vasopressin in rats with genetic and streptozocin-induced diabetes","volume":"38","author":"Brooks","year":"1989","journal-title":"Diabetes."},{"key":"10.1016\/j.peptides.2021.170683_bib1445","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s11064-007-9519-2","article-title":"Enhanced expressions of arginine vasopressin (Avp) in the hypothalamic paraventricular and supraoptic nuclei of type 2 diabetic rats","volume":"33","author":"Yi","year":"2008","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.peptides.2021.170683_bib1450","doi-asserted-by":"crossref","first-page":"503","DOI":"10.2337\/diab.28.5.503","article-title":"Plasma vasopressin in uncontrolled diabetes mellitus","volume":"28","author":"Zerbe","year":"1979","journal-title":"Diabetes."},{"key":"10.1016\/j.peptides.2021.170683_bib1455","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/BF01225456","article-title":"Plasma arginine vasopressin in diabetic ketoacidosis","volume":"16","author":"Walsh","year":"1979","journal-title":"Diabetologia."},{"key":"10.1016\/j.peptides.2021.170683_bib1460","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.cmet.2017.03.017","article-title":"Virgin Beta cells persist throughout life at a neogenic niche within pancreatic islets","volume":"25","author":"van der Meulen","year":"2017","journal-title":"Cell Metab."},{"key":"10.1016\/j.peptides.2021.170683_bib1465","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/j.cmet.2017.05.006","article-title":"W. Hong Li, J. Gromada, amino acid transporter Slc38a5 controls glucagon receptor inhibition-induced pancreatic \u03b1 cell hyperplasia in mice","volume":"25","author":"Kim","year":"2017","journal-title":"Cell Metab."},{"key":"10.1016\/j.peptides.2021.170683_bib1470","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.regpep.2004.06.010","article-title":"The role of arginine vasopressin in diabetes-associated increase in glucagon secretion","volume":"122","author":"Yibchok-Anun","year":"2004","journal-title":"Regul. Pept."},{"key":"10.1016\/j.peptides.2021.170683_bib1475","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/0167-0115(92)90075-6","article-title":"Glucose- and concentration-dependence of vasopressin-induced hormone release by mouse pancreatic islets","volume":"38","author":"Gao","year":"1992","journal-title":"Regul. Pept."},{"key":"10.1016\/j.peptides.2021.170683_bib1480","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/0196-9781(84)90109-8","article-title":"Modulation of insulin and glucagon secretion from the perfused rat pancreas by the neurohypophysial hormones and by desamino-D-arginine vasopressin (DDAVP)","volume":"5","author":"Dunning","year":"1984","journal-title":"Peptides."},{"key":"10.1016\/j.peptides.2021.170683_bib1485","article-title":"Actions of neurohypophysial peptides on pancreatic hormone release","volume":"9","author":"Dunning","year":"1984","journal-title":"Am. J. Physiol. - Endocrinol. Metab."},{"key":"10.1016\/j.peptides.2021.170683_bib1490","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1053\/meta.2002.34052","article-title":"Glucose dependency of arginine vasopressin-induced insulin and glucagon release from the perfused rat pancreas","volume":"51","author":"Abu-Basha","year":"2002","journal-title":"Metabolism."},{"key":"10.1016\/j.peptides.2021.170683_bib1495","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.biochi.2019.01.008","article-title":"Vasopressin receptors in islets enhance glucose tolerance, pancreatic beta-cell secretory function, proliferation and survival","volume":"158","author":"Mohan","year":"2019","journal-title":"Biochimie."},{"key":"10.1016\/j.peptides.2021.170683_bib1500","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1042\/bj1760893","article-title":"Stimulation by vasopressin, angiotensin and oxytocin of gluconeogenesis in hepatocyte suspension","volume":"176","author":"Whitton","year":"1978","journal-title":"Biochem. J."},{"key":"10.1016\/j.peptides.2021.170683_bib1505","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1042\/bj1360705","article-title":"Stimulation by vasopressin of glycogen breakdown and gluconeogenesis in the perfused rat liver","volume":"136","author":"Hems","year":"1973","journal-title":"Biochem. J."},{"key":"10.1016\/j.peptides.2021.170683_bib1510","doi-asserted-by":"crossref","first-page":"4631","DOI":"10.1016\/S0021-9258(18)61240-2","article-title":"Stimulation of glycogenolysis and vasoconstriction in the perfused rat liver by the thromboxane A2 analogue U-46619","volume":"262","author":"Fisher","year":"1987","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.peptides.2021.170683_bib1515","doi-asserted-by":"crossref","first-page":"E127","DOI":"10.1152\/ajpendo.00269.2016","article-title":"Acute and chronic hyperglycemic effects of vasopressin in normal rats: involvement of V1A receptors","volume":"312","author":"Taveau","year":"2017","journal-title":"Am. J. Physiol. - Endocrinol. Metab."},{"key":"10.1016\/j.peptides.2021.170683_bib1520","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S0893-133X(97)00054-7","article-title":"Plasma levels of arginine vasopressin elevated in patients with major depression","volume":"17","author":"Van Londen","year":"1997","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.peptides.2021.170683_bib1525","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1111\/dom.14462","article-title":"Weight-reducing, lipid-lowering and antidiabetic activities of a novel arginine vasopressin analogue acting at the V1a and V1b receptors in high-fat-fed mice","volume":"23","author":"Mohan","year":"2021","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.peptides.2021.170683_bib1530","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/B978-0-12-820107-7.00006-9","article-title":"Oxytocin, eating behavior, and metabolism in humans","volume":"180","author":"Kerem","year":"2021","journal-title":"Handb. Clin. Neurol."},{"key":"10.1016\/j.peptides.2021.170683_bib1535","doi-asserted-by":"crossref","first-page":"7737","DOI":"10.3390\/ijms22147737","article-title":"The Effects of Oxytocin on Appetite Regulation, Food Intake and Metabolism in Humans","volume":"22","author":"Kerem","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.peptides.2021.170683_bib1540","doi-asserted-by":"crossref","first-page":"e12805","DOI":"10.1111\/jne.12805","article-title":"The role of oxytocin in regulation of appetitive behaviour, body weight and glucose homeostasis","volume":"32","author":"Lawson","year":"2020","journal-title":"J. Neuroendocrinol."},{"key":"10.1016\/j.peptides.2021.170683_bib1545","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/cne.21872","article-title":"Expression and developmental regulation of Oxytocin (OT) and Oxytocin Receptors (OTR) in the Enteric Nervous System (ENS) and intestinal epithelium","volume":"512","author":"Welch","year":"2009","journal-title":"J. Comp. Neurol."},{"key":"10.1016\/j.peptides.2021.170683_bib1550","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.regpep.2013.03.019","article-title":"The localization of oxytocin receptors in the islets of Langerhans in the rat pancreas","volume":"183","author":"Suzuki","year":"2013","journal-title":"Regul. Pept."},{"key":"10.1016\/j.peptides.2021.170683_bib1555","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0167-0115(90)90130-O","article-title":"Effects of oxytocin on in vivo release of insulin and glucagon studied by microdialysis in the rat pancreas and autoradiographic evidence for [3H]oxytocin binding sites within the islets of Langerhans","volume":"30","author":"Stock","year":"1990","journal-title":"Regul. Pept."},{"key":"10.1016\/j.peptides.2021.170683_bib1560","doi-asserted-by":"crossref","first-page":"112","DOI":"10.2337\/diab.30.2.112","article-title":"Oxytocin infusion increases plasma insulin and glucagon levels and glucose production and uptake in the normal dog","volume":"30","author":"Altszuler","year":"1981","journal-title":"Diabetes."},{"key":"10.1016\/j.peptides.2021.170683_bib1565","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/0196-9781(84)90109-8","article-title":"Modulation of insulin and glucagon secretion from the perfused rat pancreas by the neurohypophysial hormones and by desamino-D-arginine vasopressin (DDAVP)","volume":"5","author":"Dunning","year":"1984","journal-title":"Peptides."},{"key":"10.1016\/j.peptides.2021.170683_bib1570","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3181\/00379727-182-42312","article-title":"Oxytocin increases extrapancreatic glucagon secretion and glucose production in pancreatectomized dogs","volume":"182","author":"Altszuler","year":"1986","journal-title":"Proc. Soc. Exp. Biol. Med."},{"key":"10.1016\/j.peptides.2021.170683_bib1575","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3181\/00379727-207-43788","article-title":"Oxytocin secretion is stimulated by changes in glucose metabolism","volume":"207","author":"Altszuler","year":"1994","journal-title":"Proc. Soc. Exp. Biol. Med."},{"key":"10.1016\/j.peptides.2021.170683_bib1580","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1677\/joe.0.1080293","article-title":"The mechanism of the effect of oxytocin on plasma concentrations of glucose, insulin and glucagon in conscious dogs","volume":"108","author":"Vilhardt","year":"1986","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.peptides.2021.170683_bib1585","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1159\/000181018","article-title":"Pharmacological doses of oxytocin affect plasma hormone levels modulating glucose homeostasis in normal man","volume":"30","author":"Paolisso","year":"1988","journal-title":"Horm. Res. Paediatr."},{"key":"10.1016\/j.peptides.2021.170683_bib1590","first-page":"504","article-title":"Effects of oxytocin upon the endocrine pancreas secretion and glucose turnover in normal man","volume":"123","author":"Palisso","year":"1990","journal-title":"Acta Endocrinol. (Copenh)."},{"key":"10.1016\/j.peptides.2021.170683_bib1595","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1074\/jbc.M111.277178","article-title":"Functional selective oxytocin-derived agonists discriminate between individual G protein family subtypes","volume":"287","author":"Busnelli","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.peptides.2021.170683_bib1600","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s11154-013-9260-x","article-title":"Role of oxytocin signaling in the regulation of body weight","volume":"14","author":"Blevins","year":"2013","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"10.1016\/j.peptides.2021.170683_bib1605","doi-asserted-by":"crossref","DOI":"10.1152\/ajpregu.00008.2002","article-title":"GLP-1 receptor signaling contributes to anorexigenic effect of centrally administered oxytocin in rats","volume":"283","author":"Rinaman","year":"2002","journal-title":"Am. J. Physiol. - Regul. Integr. Comp. Physiol."},{"key":"10.1016\/j.peptides.2021.170683_bib1610","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbagen.2020.129811","article-title":"Development and characterisation of novel, enzymatically stable oxytocin analogues with beneficial antidiabetic effects in high fat fed mice","volume":"1865","author":"Mohan","year":"2021","journal-title":"Biochim. Biophys. Acta - Gen. Subj."},{"key":"10.1016\/j.peptides.2021.170683_bib1615","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/ng.2607","article-title":"Genome-wide SNP and CNV analysis identifies common and low-frequency variants associated with severe early-onset obesity","volume":"45","author":"Wheeler","year":"2013","journal-title":"Nat. Genet."},{"key":"10.1016\/j.peptides.2021.170683_bib1620","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1038\/oby.2009.12","article-title":"Low sympathetic tone and obese phenotype in oxytocin-deficient mice","volume":"17","author":"Camerino","year":"2009","journal-title":"Obesity."},{"key":"10.1016\/j.peptides.2021.170683_bib1625","doi-asserted-by":"crossref","DOI":"10.1038\/srep25185","article-title":"Oxytocin protects against stress-induced cell death in murine pancreatic \u03b2-Cells","volume":"6","author":"Watanabe","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.peptides.2021.170683_bib1630","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0025565","article-title":"Mechanisms of the anti-obesity effects of oxytocin in diet-induced obese rats","volume":"6","author":"Deblon","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.peptides.2021.170683_bib1635","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1210\/js.2019-00004","article-title":"Long-acting and selective oxytocin peptide analogs show antidiabetic and antiobesity effects in male mice","volume":"3","author":"Snider","year":"2019","journal-title":"J. Endocr. Soc."},{"key":"10.1016\/j.peptides.2021.170683_bib1640","doi-asserted-by":"crossref","first-page":"4189","DOI":"10.1210\/en.2014-1466","article-title":"Divergent effects of oxytocin treatment of obese diabetic mice on adiposity and diabetes","volume":"155","author":"Altirriba","year":"2014","journal-title":"Endocrinology"},{"key":"10.1016\/j.peptides.2021.170683_bib1645","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1124\/jpet.113.202994","article-title":"Selective and potent agonists and antagonists for investigating the role of mouse oxytocin receptors","volume":"346","author":"Busnelli","year":"2013","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.peptides.2021.170683_bib1650","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.cophys.2019.10.006","article-title":"Oxytocin and vasopressin signalling and myometrial contraction","volume":"13","author":"Arrowsmith","year":"2020","journal-title":"Curr. Opin. Physiol."},{"key":"10.1016\/j.peptides.2021.170683_bib1655","doi-asserted-by":"crossref","first-page":"16311","DOI":"10.1074\/jbc.M409945200","article-title":"The oxytocin receptor antagonist atosiban inhibits cell growth via a \u201cbiased agonist\u201d mechanism","volume":"280","author":"Reversi","year":"2005","journal-title":"J. Biol. Chem."}],"container-title":["Peptides"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0196978121001911?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0196978121001911?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T09:30:51Z","timestamp":1759311051000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0196978121001911"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":331,"alternative-id":["S0196978121001911"],"URL":"https:\/\/doi.org\/10.1016\/j.peptides.2021.170683","relation":{},"ISSN":["0196-9781"],"issn-type":[{"value":"0196-9781","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Peptides in the regulation of glucagon secretion","name":"articletitle","label":"Article Title"},{"value":"Peptides","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.peptides.2021.170683","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"170683"}}